Adjuvant Clear Cell Renal Cell Carcinoma After Nephrectomy
MRKMerck & CoCatalyst overview
Research summary
This catalyst tracks a Approved update for Welireg/Belzutifan (MK-6482) + Keytruda/Pembrolizumab (MK-3475) (HIF-2α/PD-1 Blockade) in Adjuvant Clear Cell Renal Cell Carcinoma After Nephrectomy. The expected timing is based on the latest available company guidance and may change.
02/28/26:- LITESPARK-022 interim Phase 3 improved DFS in adjuvant RCC. FDA accepted supplements; PDUFA June 19, 2026. 06/15/26:- FDA approved KEYTRUDA or KEYTRUDA QLEX plus WELIREG for adjuvant ccRCC.
Verification
Confirm timing and program details against the company announcement or filing.